Related Experiment Video
Updated: Apr 12, 2026

A Minimally Invasive Method for Intratracheal Instillation of Drugs in Neonatal Rodents to Treat Lung Disease
Published on: August 4, 2021
Potassium dehydroandrographolide succinate injection for treat- ment of infantile pneumonia: a systematic review and
Insights
Potassium dehydroandrographolide succinate injection (PDS) is effective and safe for treating infantile pneumonia, improving recovery times and symptoms. Higher quality studies are needed to confirm these findings for PDS efficacy.
Area of Science:
- Pediatrics
- Pharmacology
- Evidence-Based Medicine
Background:
- Infantile pneumonia is a common respiratory infection in children.
- Potassium dehydroandrographolide succinate injection (PDS) is a potential therapeutic agent.
- Systematic evaluation of PDS for infantile pneumonia is warranted.
Purpose of the Study:
- To systematically evaluate the clinical efficacy and safety of PDS in treating infantile pneumonia.
- To synthesize evidence from randomized controlled trials (RCTs).
Main Methods:
- Searched multiple databases for RCTs of PDS in infantile pneumonia (1979-2013).
- Assessed study quality using Cochrane risk of bias tool.
- Conducted a meta-analysis using Review Manager 5.2.
Main Results:
- Included 9 RCTs with 1056 participants; study quality was generally low.
- PDS significantly improved total effective rate (RR=1.21) compared to conventional therapy.
- PDS reduced temperature recovery time (MD=-1.43) and improved rale disappearance and cough relief (MD=-1.44).
- Adverse drug reactions (rash, diarrhea) were reported but not serious.
Conclusions:
- PDS demonstrates efficacy and relative safety for infantile pneumonia treatment.
- The quality of included studies is a limitation.
- Further high-quality RCTs are recommended to confirm PDS efficacy and safety.
Objective:
To evaluate systematically the clinical efficacy and safety of potassium dehydroandrographolide succinate injection (PDS) in treatment of infantile pneumonia.
Methods:
Randomized controlled trials (RCTs) of infantile pneumonia treated by PDS were searched in China National Knowledge Infrastructure Database, China Science and Technology Journal Database, Wanfang Database, Chinese Biomedical Literature Database, PubMed, and Cochrane Library, from January 1979 to July 2013. Two reviewers independently retrieved the RCTs and extracted the information. The quality of included studies was assessed by the Cochrane risk of bias, and a Meta-analysis was conducted with Review Manager 5.2 software.
Results:
A total of 9 studies with 1056 participants were included. The quality of the studies was generally no high, only one study mentioned the random method. The Meta-analysis indicated that PDS was significantly superior to the conventional therapy in the total effective rate [relative risk (RR) = 1.21, 95% CI (1.14, 1.27), P < 0.000 01], the time of temperature recovery [mean difference (MD) = -1.43, 95% CI (-1.75, -1.11), P < 0.000 01], rale disappeared and cough relieving [MD = -1.44, 95% CI (-1.93, -0.90), P < 0.000 01]. Six adverse drug reactions from five studies mainly represented rash and diarrhea, and no serious ADRs were reported.
Conclusion:
Based on this systematic review, PDS was proved effective and relatively safe in treatment of infantile pneumonia. However the articles enrolled in the study were not high in quality, studies with higher quality should be conducted for assessment of efficacy and safety of PDS in treatment of infantile pneumonia.
Related Concept Videos
Depolarizing Blockers: Pharmocokinetics
Drug Dosing: Infants and Children
Pharmacokinetics in Pediatric Patients: Drug Excretion
Antihypertensive Drugs: Potassium-Sparing Diuretics
Skeletal Muscle Relaxants: Adverse Effects
Unlike...
Depolarizing Blockers: Mechanism of Action
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...

